Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with metastatic breast cancer who are completing planned course of chemotherapy with planned treatment break~* On stable hormone therapy for at least 2 months are also eligible for the study~* Estimated survival of at least 3 months~* No platelet inhibitor therapy within 1 month of study entry~* Platelets ≥ 100,000~* Coagulation screening tests within normal range (INR between 0.81 and 1.20)~* Normal kidney and liver function as defined by:~  * Aspartate aminotransferase(AST)/serum glutamic oxaloacetic transaminase (SGOT))/alanine aminotransferase(ALT) ≤ 2 x Institutional Normal~ * Creatinine ≤ 2 x Institutional Normal~* Able to provide signed, informed consent.~Exclusion Criteria:~* Patients going on to surgery~* Patients with a serious bleeding disorder that make them inappropriate candidates for NSAID therapy~* Patients with history of significant bleeding related to peptic ulcer disease~* Patients on standing doses of NSAIDS or platelet function inhibitors~* Patients on standing doses of anti-coagulants

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plavix and Aspirin (Type: EXPERIMENTAL): Patients will receive a 300 mg loading dose of Plavix on day 1, followed by 75 mg/day, and aspirin 81 mg per day starting day 1. Treatment will be continued until the treating physician elects to resume systemic therapy for the treatment of breast cancer or until unacceptable toxicity is observed. A pill diary will be collected monthly to monitor patients' compliance with the medication regimen.
- Observation only (Type: NO_INTERVENTION): Observation by treating physician

Based on this trial design, predict the completion outcome and termination type (if applicable).